Format

Send to

Choose Destination
Blood Rev. 2016 May;30(3):157-67. doi: 10.1016/j.blre.2015.10.003. Epub 2015 Nov 6.

Chimeric antigen receptor T cell therapy: 25years in the making.

Author information

1
Division of Hematology/Oncology, University of Pennsylvania Health System, Philadelphia, PA, USA. Electronic address: saar.gill@uphs.upenn.edu.
2
Division of Hematology/Oncology, University of Pennsylvania Health System, Philadelphia, PA, USA.

Abstract

Chimeric antigen receptor (CAR) T cell therapy of cancer is generating enormous enthusiasm. Twenty-five years after the concept was first proposed, major advances in molecular biology, virology, and good manufacturing practices (GMP)-grade cell production have transformed antibody-T cell chimeras from a scientific curiosity to a fact of life for academic cellular immunotherapy researchers and, increasingly, for patients. In this review, we explain the preclinical concept, outline how it has been translated to the clinic, and draw lessons from the first years of CAR T cell therapy for the practicing clinician.

KEYWORDS:

Adoptive immunotherapy; Chimeric antigen receptor T cells

PMID:
26574053
DOI:
10.1016/j.blre.2015.10.003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center